Inside the Market of Emerging Biotechs

For nearly a decade, biotech companies and their venture backers enjoyed a historic boom. Although momentum has come to a halt, many of the largest venture investors remain flush with cash, while progress in gene editing, messenger RNA and cell therapies promise new kinds of medicines in the future.

INCLUDED IN THIS TRENDLINE

  • Cell and gene therapy manufacturing: the next generation of startups
  • European VCs raise fresh funds for life sciences investing
  • Acelyrin IPO tests investor demand for biotech stock offerings

Request Free!